

SENTARA COMMUNITY PLAN (MEDICAID)

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-800-750-9692**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

Drug Requested: Exdensur® (depemokimab-ulaa) (Pharmacy) (Non-Preferred)

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member Sentara #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone Number: _____ Fax Number: _____

NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ Length of Therapy: _____

Diagnosis: _____ ICD Code, if applicable: _____

Weight (if applicable): _____ Date weight obtained: _____

Recommended Dosage: Adults and adolescents ≥ 12 years: 100 mg SubQ, single-dose prefilled auto-injector or single dose prefilled syringe, once every 6 months

***Sentara Health Plans considers the use of concomitant therapy with Cinqair®, Dupixent®, Exdensur®, Fasenra®, Nucala®, and Xolair® to be experimental and investigational. Safety and efficacy of these combinations have **NOT** been established and will **NOT** be permitted. In the event a member has an active Cinqair®, Dupixent®, Exdensur®, Fasenra®, Nucala®, and Xolair® authorization on file, all subsequent requests for Exdensur® will **NOT** be approved.**

(Continued on next page)

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

- ☐ Has the member been approved for Exdensusur[®] previously through the Sentara medical department?
☐ Yes ☐ No

☐ **DIAGNOSIS: Severe Asthma**

Initial Authorization: 6 months

1. Is the member 12 years of age or older? ☐ Yes ☐ No
2. Does the member have a diagnosis of severe* asthma? ☐ Yes ☐ No
3. Does the member have asthma with an eosinophilic phenotype defined as baseline blood eosinophils ≥ 150 cells/ μ L? ☐ Yes ☐ No
4. Will coadministration with another monoclonal antibody be avoided (e.g., omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, tezepelumab-ekko)? ☐ Yes ☐ No
5. Will Exdensusur[®] be used for add-on maintenance treatment in members regularly receiving **both** of the following (unless otherwise contraindicated):
 - Medium to high dose inhaled corticosteroids **AND**
 - An additional controller medication (e.g., long-acting beta agonist, leukotriene modifiers?)☐ Yes ☐ No
6. Has the member had two or more exacerbations in the previous year requiring oral or injectable corticosteroid treatment (in addition to the regular maintenance therapy defined above) or one exacerbation resulting in hospitalization? ☐ Yes ☐ No
7. Does the member have at least one of the following for assessment of clinical status:
 - Use of systemic corticosteroids
 - Use of inhaled corticosteroids
 - Number of hospitalizations, ER visits, or unscheduled visits to healthcare provider due to condition
 - Forced expiratory volume in 1 second (FEV₁)?☐ Yes ☐ No
8. Has the member tried and failed two preferred agents listed on the PDL where applicable for the requested product's intended use? ☐ Yes ☐ No

(Continued on next page)

☐ **DIAGNOSIS: Severe Asthma**

Reauthorization: 12 months. Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

1. Does the member have improvement in asthma symptoms or asthma exacerbations as evidenced by a decrease in one or more of the following:
 - Use of systemic corticosteroids
 - Hospitalizations
 - ER visits
 - Unscheduled visits to healthcare provider
 - Improvement from baseline in forced expiratory volume in 1 second (FEV₁)?

☐ Yes ☐ No

***Components of severity for classifying asthma as *severe* may include any of the following (not all inclusive):**

- Asthma that remains uncontrolled despite optimized treatment with high-dose ICS-LABA
- Asthma that requires high-dose ICS-LABA to prevent it from being uncontrolled
- Symptoms throughout the day
- Nighttime awakenings, often 7 times per week
- SABA use for symptom control occurs several times per day
- Extremely limited normal activities
- Lung function (percent predicted FEV₁) < 60%
- Exacerbations requiring oral systemic corticosteroids are generally more frequent and intense relative to moderate asthma

Medication being provided by Specialty Pharmacy - PropriumRx

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****